濮阳东方医院看男科收费低濮阳东方看妇科价格低,濮阳东方医院看男科病非常便宜,濮阳东方医院做人流手术非常专业,濮阳东方医院妇科做人流好不好,濮阳东方医院男科看早泄很靠谱,濮阳东方医院男科治疗阳痿非常好,濮阳东方妇科医院看病好又便宜

The Department of Homeland Security and the Pentagon are having initial discussions that could lead to a 45-day extension of the southern border mission for US troops, according to two administration officials.DHS would have to make a specific request to the Pentagon. Under the current plan, the border mission is scheduled to end December 15.The discussion comes following tensions at the border Sunday, when about?500 migrants overwhelmed police blockades on the Mexican side of the San Ysidro port of entry, two journalists in Tijuana told CNN. US authorities used tear gas to disperse the crowds, which included families and small children, and more than 100 migrants were arrested.One of the officials said that "based on what happened on Sunday" DHS still wants the help of the Defense Department, adding that "the threat has not gone away."The agencies are also discussing whether some engineers who worked on fortifying crossing points in Arizona and Texas can now be sent home and whether more troops will shift to California.President Donald Trump sent about 5,800 federal troops to the border after spending the weeks leading up to the midterm elections decrying a procession of migrants that was still thousands of miles from the US border. Last week, Trump granted the troops new powers to aid in "crowd control, temporary detention and cursory search" while protecting Customs and Border Protection personnel from the migrants, should they engage in violence.On Wednesday afternoon, Secretary of Defense James Mattis said the Pentagon was ready to "react to the Department of Homeland Security" if it asks for any extensions. Mattis added, "Right now we have no new requests, although we are discussing every day the situation and so I can't forecast when that will be."Last week Homeland Secretary Kirstjen Nielsen said she had "no doubt that DoD will continue to be our partners in this mission until it is resolved."NPR was first to report the possible extension. 2004

The Flores family has been farming dates for three generations.For the past few years, Marco Flores, owner of San Marcos Date Farm, says he’s seen major changes in temperature and weather patterns.“It’s drier than it used to be,” he said of the land his father bought in California’s Coachella Valley more than 55 years ago. “It used to be a lot more moist before.”These are conditions his 300 fruit-producing palm trees don’t like.“Sometimes there’s no rain,” Flores said. “The impact of climate change is definitely doing something to them.”Similar concerns are being expressed across the planet.“Climate change is impacting agriculture and farmers abilities,” said Paul Minehart of the Syngenta Group, a global agricultural innovation company.Minehart’s team recently published a study showing 72% of farmers they interviewed from around the world are worried about climate changes impacting crop yields.“It’s coming down to, especially in the United States, is the unpredictable weather patterns that are beginning to emerge,” he said.Minehart says those unpredictable weather patterns include unusual droughts and flooding in America and extremely arid conditions in other countries. Conditions that could impact farmers production and profits.“If you have fewer crops than the price could go up,” he said. “That could impact the overall cost of producing food and then at the consumer level buying the food.”Marco Juarez is the third generation of Flores farmers at San Marcos Date Farm.He says while using more water could cause his family to raise their prices from a pound for dates, there’s another growing concern: getting skilled workers to take a job in this heat.“I don’t think anyone really wants to work in this,” he said. “It slowly drives people away. I mean, who wants to be here in 120 degrees?” 1826

The CBS board of directors is in the process of picking outside counsel to conduct an investigation after company CEO Les Moonves was accused of sexual misconduct.In a statement, CBS said that "no other action" was taken on the matter at Monday's board meeting.The meeting was scheduled before a bombshell report in The New Yorker Friday detailed allegations against the CEO. Six women told the magazine that Moonves sexually harassed them.In a statement to The New Yorker that was also obtained by CNNMoney on Friday, Moonves said he has "promoted a culture of respect and opportunity for all employees" throughout his tenure at CBS."I recognize that there were times decades ago when I may have made some women uncomfortable by making advances," Moonves said. "Those were mistakes, and I regret them immensely. But I always understood and respected — and abided by the principle — that 'no' means 'no,' and I have never misused my position to harm or hinder anyone's career."The idea that Moonves should step aside during the probe was raised by at least some board members this weekend, according to one source who spoke to CNNMoney on Sunday.The board also said on Monday that it would postpone its annual meeting of stockholders, which was scheduled to be held August 10. A new date has not yet been announced. It was not clear why the board decided to reschedule that meeting. 1400

The Food and Drug Administration is investigating an outbreak of Listeria that has killed at least one person.The FDA, CDC and public health officials are looking into ten cases of Listeria monocytogenes infections reported in Florida, Massachusetts and New York. One person has died, the only available information is that the person lived in Florida.Genome sequencing of the Listeria bacteria isolated from those infected shows the ten people in this outbreak are more likely to share a common source of infection, according to the FDA. Samples were taken from patients between August 6 and October 3.In interviews with nine of the infected people, they all reported eating Italian-style meats recently, like salami, mortadella, or prosciutto, according to the FDA.Public health investigators have not found a common type of deli meat or common supplier among the patients at this time.The patients in this outbreak range in age from 40-to-89 years old, and all of them needed to be hospitalized.Listeria can cause different symptoms, depending on the person and part of the body affected, according to the Centers for Disease Control and Prevention. Symptoms include headache, stiff neck, confusion, loss of balance, fever and muscle aches. 1251

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201